Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.42 |
| ▸ | SYK | P43405 | 5/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894787 | 0.91 | PTPN1 (0.43) | PTPN1PTPN2FFAR1FFAR4 | |
| SCHEMBL2897003 | 0.89 | PTPN1 (0.44) | PTPN1PTPN2SMN1; SMN2 | |
| SCHEMBL2889272 | 0.88 | PTPN2 (0.56) | PTPN1PTPN2SYK | |
| SCHEMBL2892378 | 0.85 | PTPN1 (0.45) | PTPN1PTPN2 | |
| SCHEMBL22412755 | 0.80 | PTPN1 (0.53) | PTPN1PTPN2 | |
| SCHEMBL30026035 | 0.80 | PTPN1 (0.53) | PTPN1PTPN2 | |
| SCHEMBL31277020 | 0.80 | PTPN1 (0.48) | PTPN1PTPN2 | |
| SCHEMBL23539818 | 0.79 | PTPN1 (0.43) | PTPN1PTPN2 | |
| SCHEMBL22412173 | 0.78 | PTPN1 (0.66) | PTPN1PTPN2 | |
| SCHEMBL2896986 | 0.78 | PTPN1 (0.63) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | PTPN1 11/4885PTPN2 5/4885SYK 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.